1. Avelumab plus carboplatin is safe and effective in treating metastatic castration-resistant prostate cancer, according to an open-label Phase Ib study.
2. The combination therapy showed promising results in terms of overall response rate and progression-free survival.
3. Adverse events were manageable and consistent with the known safety profiles of both drugs.